Milestone Pharmaceuticals Inc.
MIST
$2.15
$0.073.37%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -100.00% |
| SG&A Expenses | 47.03% | 25.42% | 15.22% | -10.63% | -5.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.40% | 11.60% | -7.00% | -32.20% | -33.56% |
| Operating Income | -31.40% | -11.60% | 7.00% | 31.09% | 28.67% |
| Income Before Tax | -35.65% | -14.71% | 5.74% | 30.44% | 27.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.65% | -14.71% | 5.74% | 30.44% | 27.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.65% | -14.71% | 5.74% | 30.44% | 27.82% |
| EBIT | -31.40% | -11.60% | 7.00% | 31.09% | 28.67% |
| EBITDA | -31.48% | -11.62% | 7.01% | 31.16% | 28.74% |
| EPS Basic | -1.49% | 17.47% | 37.15% | 51.28% | 41.61% |
| Normalized Basic EPS | -1.51% | 17.45% | 37.14% | 51.28% | 41.61% |
| EPS Diluted | -1.49% | 17.47% | 37.15% | 51.28% | 41.61% |
| Normalized Diluted EPS | -1.51% | 17.45% | 37.14% | 51.28% | 41.61% |
| Average Basic Shares Outstanding | 30.97% | 31.02% | 47.89% | 44.79% | 31.50% |
| Average Diluted Shares Outstanding | 30.97% | 31.02% | 47.89% | 44.79% | 31.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |